MoCD Type A is a rare, inborn error of metabolism caused by mutations in the MOCS1 gene that results in toxic sulfite accumulation in the brain. Nulibry ...
Nulibry replaces missing cyclic pyranopterin monophosphate, which is needed to reduce levels of neurotoxic sulfites. The Food and Drug Administration (FDA) has approved Nulibry ™ (fosdenopterin) for ...
Today, the U.S. Food and Drug Administration approved Nulibry (fosdenopterin) for injection to reduce the risk of death due to Molybdenum Cofactor Deficiency Type A, a rare, genetic, metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results